Spatial separation of the processing and MHC class I loading compartments for cross-presentation of the tumor-associated antigen HER2/neu by human dendritic cells

被引:11
作者
Baleeiro, Renato B. [1 ]
Rietscher, Rene [2 ]
Diedrich, Andrea [3 ]
Czaplewska, Justyna A. [4 ,5 ]
Lehr, Claus-Michael [2 ,6 ]
Scherliess, Regina [3 ]
Hanefeld, Andrea [7 ]
Gottschaldt, Michael [4 ,5 ]
Walden, Peter [1 ]
机构
[1] Charite, Dept Dermatol Venerol & Allergol, D-13353 Berlin, Germany
[2] Univ Saarland, Helmholtz Ctr Infect Res, Helmholtz Inst Pharmaceut Res Saarland HIPS, D-66123 Saarbrucken, Germany
[3] Univ Kiel, Dept Pharmaceut & Biopharmaceut, Kiel, Germany
[4] Univ Jena, Lab Organ & Macromol Chem IOMC, Jena, Germany
[5] Univ Jena, JCSM, Jena, Germany
[6] Univ Saarland, Biopharmaceut & Pharmaceut Technol, D-66123 Saarbrucken, Germany
[7] Merck KGaA, Open Innovat Management, Darmstadt, Germany
来源
ONCOIMMUNOLOGY | 2015年 / 4卷 / 11期
关键词
cross-presentation; cancer; dendritic cells; HER2/neu; nanoparticles; tumor-associated antigens; vaccine; CONTROLS PHAGOSOMAL PH; HER-2/NEU ONCOPROTEIN; EXOGENOUS ANTIGENS; DEGRADATION ERAD; SOLUBLE-PROTEIN; HUMAN CD8(+); T-CELLS; ENDOSOMES; MATURATION; RESPONSES;
D O I
10.1080/2162402X.2015.1047585
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Cross-presentation is the process by which professional antigen presenting cells (APCs) (B cells, dendritic cells (DCs) and macrophages) present endocytosed antigens (Ags) via MHC-I to CD8(+) T cells. This process is crucial for induction of adaptive immune responses against tumors and infected cells. The pathways and cellular compartments involved in cross-presentation are unresolved and controversial. Among the cells with cross-presenting capacity, DCs are the most efficient, which was proposed to depend on prevention of endosomal acidification to block degradation of the epitopes. Contrary to this view, we show in this report that some cargoes induce strong endosomal acidification following uptake by human DCs, while others not. Moreover, processing of the tumor-associated antigen HER2/neu delivered in nanoparticles (NP) for cross-presentation of the epitope HER2/neu(369-377) on HLA-A2 depended on endosomal acidification and cathepsin activity as well as proteasomes, and newly synthesized HLA class I. However, the HLA-A*0201/HER2/neu(369-377) complexes were not found in the endoplasmic reticulum (ER) nor in endolysosomes but in hitherto not described vesicles. The data thus indicate spatial separation of antigen processing and loading of MHC-I for cross-presentation: antigen processing occurs in the uptake compartment and the cytosol whereas MHC-I loading with peptide takes place in a distinct subcellular compartment. The findings further elucidate the cellular pathways involved in the cross-presentation of a full-length, clinically relevant tumor-associated antigen by human DCs, and the impact of the vaccine formulation on antigen processing and CD8(+) T cell induction.
引用
收藏
页数:11
相关论文
共 51 条
  • [1] Chloroquine enhances human CD8+ T cell responses against soluble antigens in vivo
    Accapezzato, D
    Visco, V
    Francavilla, V
    Molette, C
    Donato, T
    Paroli, M
    Mondelli, MU
    Doria, M
    Torrisi, MR
    Barnaba, V
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2005, 202 (06) : 817 - 828
  • [2] Dendritic cells acquire antigen from apoptotic cells and induce class I restricted CTLs
    Albert, ML
    Sauter, B
    Bhardwaj, N
    [J]. NATURE, 1998, 392 (6671) : 86 - 89
  • [3] A CD74-dependent MHC class I endolysosomal cross-presentation pathway
    Basha, Genc
    Omilusik, Kyla
    Chavez-Steenbock, Ana
    Reinicke, Anna T.
    Lack, Nathan
    Choi, Kyung Bok
    Jefferies, Wilfred A.
    [J]. NATURE IMMUNOLOGY, 2012, 13 (03) : 237 - U53
  • [4] Immunogenic HER-2/neu peptides as tumor vaccines
    Baxevanis, CN
    Sotiriadou, NN
    Gritzapis, AD
    Sotiropoulou, PA
    Perez, SA
    Cacoullos, NT
    Papamichail, M
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2006, 55 (01) : 85 - 95
  • [5] Immunobiology of HER-2/neu oncoprotein and its potential application in cancer immunotherapy
    Baxevanis, CN
    Sotiropoulou, PA
    Sotiriadou, NN
    Papamichail, M
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2004, 53 (03) : 166 - 175
  • [6] Investigation into the catalytic role for the tryptophan residues within domain III of Pseudomonas aeruginosa exotoxin A
    Beattie, BK
    Prentice, GA
    Merrill, AR
    [J]. BIOCHEMISTRY, 1996, 35 (48) : 15134 - 15142
  • [7] Cross-priming of naive CD8 T cells against melanoma antigens using dendritic cells loaded with killed allogeneic melanoma cells
    Berard, F
    Blanco, P
    Davoust, J
    Neidhart-Berard, EM
    Nouri-Shirazi, M
    Taquet, N
    Rimoldi, D
    Cerottini, JC
    Banchereau, J
    Palucka, AK
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2000, 192 (11) : 1535 - 1543
  • [8] BEVAN MJ, 1976, J IMMUNOL, V117, P2233
  • [9] Spatial and mechanistic separation of cross-presentation and endogenous antigen presentation
    Burgdorf, Sven
    Schoelz, Christian
    Kautz, Andreas
    Tampe, Robert
    Kurts, Christian
    [J]. NATURE IMMUNOLOGY, 2008, 9 (05) : 558 - 566
  • [10] Sec22b Regulates Phagosomal Maturation and Antigen Crosspresentation by Dendritic Cells
    Cebrian, Ignacio
    Visentin, Geraldine
    Blanchard, Nicolas
    Jouve, Mabel
    Bobard, Alexandre
    Moita, Catarina
    Enninga, Jost
    Moita, Luis F.
    Amigorena, Sebastian
    Savina, Ariel
    [J]. CELL, 2011, 147 (06) : 1355 - 1368